tradingkey.logo

enVVeno Medical Corp

NVNO
10.420USD
+1.070+11.44%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
6.02MCap. mercado
PérdidaP/E TTM

enVVeno Medical Corp

10.420
+1.070+11.44%

Más Datos de enVVeno Medical Corp Compañía

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

Información de enVVeno Medical Corp

Símbolo de cotizaciónNVNO
Nombre de la empresaenVVeno Medical Corp
Fecha de salida a bolsaMay 31, 2018
Director ejecutivoBerman (Robert A)
Número de empleados37
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 31
Dirección70 Doppler
CiudadIRVINE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92618
Teléfono19492612900
Sitio Webhttps://envveno.com/
Símbolo de cotizaciónNVNO
Fecha de salida a bolsaMay 31, 2018
Director ejecutivoBerman (Robert A)

Ejecutivos de enVVeno Medical Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
Otro
71.72%
Accionistas
Accionistas
Proporción
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
Otro
71.72%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
9.48%
Investment Advisor
8.80%
Private Equity
7.67%
Hedge Fund
7.22%
Investment Advisor/Hedge Fund
1.68%
Research Firm
1.18%
Venture Capital
0.18%
Otro
63.79%

Participación institucional

Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
80
169.95K
25.92%
-68.67K
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Satterfield (Thomas A Jr)
1.82M
9.02%
+1.82M
--
Nov 14, 2025
Perceptive Advisors LLC
1.76M
8.7%
+474.07K
+36.89%
Sep 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
6.72%
+500.00K
+58.19%
Sep 30, 2025
CM Management, LLC
600.00K
2.97%
+600.00K
--
Sep 30, 2025
The Vanguard Group, Inc.
861.19K
4.26%
+162.85K
+23.32%
Sep 30, 2025
Berman (Robert Andrew)
222.24K
1.1%
+200.00K
+899.44%
Oct 17, 2025
Geode Capital Management, L.L.C.
201.24K
1%
+1.74K
+0.87%
Sep 30, 2025
J.P. Morgan Securities LLC
182.32K
0.9%
+22.00
+0.01%
Sep 30, 2025
Susquehanna International Group, LLP
154.47K
0.76%
+154.47K
--
Sep 30, 2025
Ver más

ETFs relacionados

Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI